دورية أكاديمية

PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma

التفاصيل البيبلوغرافية
العنوان: PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma
المؤلفون: Cuccaro A., Bellesi S., Galli E., Corrente F., Cupelli E., Fatone F., Alma E., Viscovo M., D'Alo F., Annunziata S., Rufini V., Giordano A., De Stefano V., Larocca L. M., Hohaus S.
المساهمون: Cuccaro, Annarosa, Bellesi, Silvia, Galli, Eugenio, Zangrilli, I., Corrente, Francesco, Cupelli, Elisa, Fatone, Federica, Maiolo, E., Alma, Eleonora, Viscovo, Marcello, D'Alo', Francesco, Annunziata, Salvatore, Martini, M., Rufini, Vittoria, Giordano, Alessandro, De Stefano, Valerio, Larocca, Luigi Maria, Hohaus, Stefan
بيانات النشر: John Wiley and Sons Inc
سنة النشر: 2022
المجموعة: Università Cattolica del Sacro Cuore: PubliCatt
مصطلحات موضوعية: Hodgkin lymphoma, PD-L1, immune checkpoint, prognosis, Settore MED/15 - MALATTIE DEL SANGUE
الوصف: Hodgkin lymphoma (HL) is a neoplastic disease in which the inflammatory microenvironment plays a pivotal role in the tumorigenesis. Neutrophilia is a typical finding in HL at diagnosis and, in particular, in association with lymphocytopenia, is a negative prognostic factor. As the immune checkpoint Programmed Death (PD)-L1/PD-1 has become an important therapeutic target, we were interested in the expression of PD-L1 in peripheral blood (PB) leukocytes using flow cytometry and RT-PCR in patients with HL and healthy controls. Granulocytes were the major PB cell fraction expressing PD-L1. PD-L1 expression on granulocytes was higher in patients with HL than in controls and correlated with lower T-cell numbers in PB. We analyzed for associations between PD-L1 expression in PB granulocytes at the time of diagnosis with patient characteristics and outcome in 126 patients with HL treated with standard chemotherapy adriamycin, bleomycin, vinblastine, and dacarbazine. Increased PD-L1 expression in PB associated with advanced disease, systemic symptoms, positive interim positron emission tomography, and inferior progression-free survival (PFS). PFS at 4 years was 81% (95% C.I., 71–87%) in patients with normal PD-L1 expression and 56% (95% C.I., 35–72%) in patients with higher-than-normal PD-L1 expression (p=0.002). In conclusion, PD-L1 expression in PB could become a potentially actionable prognostic factor in HL.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35060170; info:eu-repo/semantics/altIdentifier/wos/WOS:000744794500001; volume:2022; issue:N/A; firstpage:N/A; lastpage:N/A; issueyear:2022; journal:JOURNAL OF LEUKOCYTE BIOLOGY; http://hdl.handle.net/10807/198513Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85123300473
DOI: 10.1002/JLB.5AB0121-041R
الإتاحة: https://doi.org/10.1002/JLB.5AB0121-041RTest
http://hdl.handle.net/10807/198513Test
رقم الانضمام: edsbas.F373F14A
قاعدة البيانات: BASE